Medication info
Glucita Duo Tablet 50/500 mg

Glucita Duo Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hanol BioPharma Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202204577 · Approved 2022.12.21 · Insurance code 655605630

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients in whom this medication is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may begin at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment Due to its metformin component, this medication should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients in whom this medication is contraindicated).

Ingredients

Manufacturer
Hanol BioPharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medicine contains both sitagliptin and metformin, which helps patients with type 2 diabetes control their blood sugar. It is effective when combined with dietary management and regular exercise for blood sugar management. It helps maintain stable blood sugar levels, making it a good choice for diabetes treatment.

How to take

Adult dose

For antidiabetic therapy, the dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients in whom this medication is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may begin at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment Due to its metformin component, this medication should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients in whom this medication is contraindicated).

Precautions

This medicine is used in the treatment of diabetes and requires careful attention when taken. First, this medication may cause allergic reactions; if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a physician. Additionally, pancreatitis or inflammation of the pancreas may occur; if symptoms such as severe abdominal pain, vomiting, or nausea arise, visit a hospital immediately. One of the ingredients in this medication may pose risks to patients with reduced kidney function, so it should not be taken if kidney function is impaired. Patients experiencing acute issues with heart or kidney, such as acute heart failure, myocardial infarction, or severe infections, should also refrain from using this medication. Especially, it is necessary to temporarily discontinue this drug before and after tests using contrast agents and resume only after normal kidney function is confirmed. Women who are pregnant or may become pregnant, and breastfeeding women should not take this medication. This medicine can cause hypoglycemia, so caution is particularly needed if meals are missed, eaten irregularly, excessive exercise is done, or if taken with other blood glucose-lowering agents. During treatment, regular monitoring of blood glucose, kidney function, liver function, and blood tests is recommended, along with periodic checks of vitamin B12 levels. Alcohol consumption may increase the risk of side effects from this drug, so abstinence from alcohol during treatment is advised. If surgery is required, discontinue the medication 48 hours prior to surgery and only resume it after normal kidney function is recovered following the operation. If severe joint pain, skin rashes, or blisters develop while taking this medication, notify your doctor immediately and seek treatment. In case of overdose, seek emergency treatment immediately, and if necessary, blood dialysis may be performed to remove the medication. The safety and efficacy of this medication in children have not been established, and elderly patients may need dosage adjustment and close monitoring due to decreased kidney function. It is important to adhere to these precautions and consult medical personnel immediately if any abnormal symptoms arise.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • blistering dermatosis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • gastrointestinal disturbance
  • itching
  • acute renal failure
  • dermatitis
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly closed container to prevent air and moisture. It is recommended to keep the storage temperature between 1 and 30 degrees Celsius. Proper storage can help maintain the drug's efficacy for a longer period.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.